Antibody Information
General Information of This Antibody
| Antibody ID | ANI0CDJLA |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | J591 |
|||||
| Organization | Weill Cornell Medical |
|||||
| Indication | Prostate cancer |
|||||
| Synonyms |
HUJ-591; HUJ591-GS; Rosopatamab
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Chimeric IgG1-kappa |
|||||
| Antigen Name | Glutamate carboxypeptidase 2 (FOLH1) |
Antigen Info | ||||
| ChEMBI ID | ||||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
| Heavy Chain Sequence |
EVQLVQSGPEVKKPGATVKISCKTSGYTFTEYTIHWVKQAPGKGLEWIGNINPNNGGTTY
NQKFEDKATLTVDKSTDTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLLTVSSASTKG PSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSL SSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFL FPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQ VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNV FSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Varible Domain |
EVQLVQSGPEVKKPGATVKISCKTSGYTFTEYTIHWVKQAPGKGLEWIGNINPNNGGTTY
NQKFEDKATLTVDKSTDTAYMELSSLRSEDTAVYYCAAGWNFDYWGQGTLLTVSS Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 1 |
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 2 |
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK Click to Show/Hide
|
|||||
| Heavy Chain Constant Domain 3 |
GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
|
|||||
| Heavy Chain Hinge Region |
EPKSCDKTHTCPPCP
Click to Show/Hide
|
|||||
| Heavy Chain CDR 1 |
GYTFTEYT
Click to Show/Hide
|
|||||
| Heavy Chain CDR 2 |
INPNNGGT
Click to Show/Hide
|
|||||
| Heavy Chain CDR 3 |
AAGWNFDY
Click to Show/Hide
|
|||||
| Light Chain Sequence |
DIQMTQSPSSLSTSVGDRVTLTCKASQDVGTAVDWYQQKPGPSPKLLIYWASTRHTGIPS
RFSGSGSGTDFTLTISSLQPEDFADYYCQQYNSYPLTFGPGTKVDIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain Varible Domain |
DIQMTQSPSSLSTSVGDRVTLTCKASQDVGTAVDWYQQKPGPSPKLLIYWASTRHTGIPS
RFSGSGSGTDFTLTISSLQPEDFADYYCQQYNSYPLTFGPGTKVDIK Click to Show/Hide
|
|||||
| Light Chain Constant Domain |
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
|
|||||
| Light Chain CDR 1 |
QDVGTA
Click to Show/Hide
|
|||||
| Light Chain CDR 2 |
WAS
Click to Show/Hide
|
|||||
| Light Chain CDR 3 |
QQYNSYPLT
Click to Show/Hide
|
|||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
MEDI-3726 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Composite Response Rate (RR) |
12.10%
|
|||
| Patients Enrolled |
Patients with metastatic castration-resistant prostate cancer after disease progression on abiraterone and/or enzalutamide and taxane-based chemotherapy.
|
||||
| Administration Dosage |
Administered at 0.015-0.30 mg/kg intravenously every 3 weeks until disease progression/unacceptable toxicity; The MTD was not identified; the MAD was 0.30 mg/kg.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02991911 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1/1b multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, immunogenicity, and antitumor activity of MEDI3726 in subjects with metastatic castration resistant prostate cancer who have received prior treatment with abiraterone or enzalutamide.
|
||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 15.86% (Day 26) | High PSMA expression (PSMA+++; 250,494 PSMA molecules/cell) | ||
| Method Description |
The inhibitory activity of MEDI3726 against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.33 mg/kg MEDI3726.
|
||||
| In Vivo Model | PC-3 CDX model | ||||
| In Vitro Model | Prostate carcinoma | PC-3 cells | CVCL_0035 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 36.17% (Day 19) | Moderate PSMA expression (PSMA++; 43,766 PSMA molecules/cell) | ||
| Method Description |
The inhibitory activity of MEDI3726 against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.11 mg/kg MEDI3726.
|
||||
| In Vivo Model | PC-3 CDX model | ||||
| In Vitro Model | Prostate carcinoma | LNCaP cells | CVCL_0395 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 45.68% (Day 26) | High PSMA expression (PSMA+++; 250,494 PSMA molecules/cell) | ||
| Method Description |
The inhibitory activity of MEDI3726 against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 1 mg/kg MEDI3726.
|
||||
| In Vivo Model | PC-3 CDX model | ||||
| In Vitro Model | Prostate carcinoma | PC-3 cells | CVCL_0035 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 68.20% (Day 19) | Moderate PSMA expression (PSMA++; 43,766 PSMA molecules/cell) | ||
| Method Description |
The inhibitory activity of MEDI3726 against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.33 mg/kg MEDI3726.
|
||||
| In Vivo Model | PC-3 CDX model | ||||
| In Vitro Model | Prostate carcinoma | LNCaP cells | CVCL_0395 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 76.95% (Day 19) | High PSMA expression (PSMA+++; 250,494 PSMA molecules/cell) | ||
| Method Description |
The inhibitory activity of MEDI3726 against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 1 mg/kg MEDI3726.
|
||||
| In Vivo Model | PC-3 CDX model | ||||
| In Vitro Model | Prostate carcinoma | LNCaP cells | CVCL_0395 | ||
| Experiment 6 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 93.55% (Day 20) | Negative PSMA expression (PSMA-) | ||
| Method Description |
The inhibitory activity of MEDI3726 against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 0.33 mg/kg MEDI3726.
|
||||
| In Vivo Model | PC-3 CDX model | ||||
| In Vitro Model | Prostate carcinoma | 22RV1 cells | CVCL_1045 | ||
| Experiment 7 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 98.71% (Day 20) | Negative PSMA expression (PSMA-) | ||
| Method Description |
The inhibitory activity of MEDI3726 against cancer cell growth was evaluated in various human cancer cell lines in vivo. The cells were treated with 1 mg/kg MEDI3726.
|
||||
| In Vivo Model | PC-3 CDX model | ||||
| In Vitro Model | Prostate carcinoma | 22RV1 cells | CVCL_1045 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.